XML 54 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Stockholders' Equity (USD $)
In Thousands, except Share data
Total
Predecessor
Successor
Common Stock
Predecessor
Common Stock
Successor
Additional Paid-In Capital
Predecessor
Additional Paid-In Capital
Successor
Deficit Accumulated During Development Stage
Successor
Treasury Stock
Successor
Parent Company's Net Deficit
Predecessor
Beginning balance at Dec. 31, 2003   $ (89)   $ 0   $ 0       $ (89)
Beginning balance, shares at Dec. 31, 2003       0            
Net loss   (3,272)               (3,272)
Net transactions with Parent   2,393               2,393
Ending balance at Dec. 31, 2004   (968)   0   0       (968)
Ending balance, shares at Dec. 31, 2004       0            
Net loss   (2,209)               (2,209)
Net transactions with Parent   2,727               2,727
Ending balance at Dec. 31, 2005   (450)   0   0       (450)
Ending balance, shares at Dec. 31, 2005       0            
Net loss   (2,405)               (2,405)
Net transactions with Parent   2,587               2,587
Ending balance at Dec. 31, 2006   (268)   0   0     0 (268)
Ending balance, shares at Dec. 31, 2006       0            
Beginning balance at Apr. 03, 2006     0   0   0 0 0  
Beginning balance, shares at Apr. 03, 2006         0          
Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares         1,624,278          
Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)     2       2      
Ending balance at Dec. 31, 2006     2 0 0 0 2 0 0  
Ending balance, shares at Dec. 31, 2006       0 1,624,278          
Common stock issued to CytRx for contribution of RXi and other assets, shares         7,040,318          
Common stock issued to CytRx for contribution of RXi and other assets     48   1   47      
Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares         3,273,292          
Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)     15,348       15,348      
Common stock issued to CytRx for reimbursement of expenses, shares         188,387          
Common stock issued to CytRx for reimbursement of expenses     978       978      
Expenses incurred by CytRx for RXi     831       831      
Common stock issued to UMMS for additional intellectual properties, shares         462,112          
Common stock issued to UMMS for additional intellectual properties     2,311       2,311      
Common stock issued to directors, shares         30,000          
Common stock issued to directors     150       150      
Common stock issued upon exercise of stock options, shares         66,045          
Common stock issued upon exercise of stock options     331       331      
Stock based compensation expense for directors and employees     1,048       1,048      
Stock based compensation expense for services     766       766      
Net loss     (10,990)         (10,990)    
Ending balance at Dec. 31, 2007     10,823   1   21,812 (10,990) 0  
Ending balance, shares at Dec. 31, 2007         12,684,432          
Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares         1,073,299          
Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)     7,918       7,918      
Common stock issued upon exercise of stock options, shares         5,500          
Common stock issued upon exercise of stock options     26       26      
Stock based compensation expense for directors and employees     2,211       2,211      
Stock based compensation expense for services     1,613       1,613      
Value of common stock warrants issued (expense) in exchange for services     750       750      
Net loss     (14,373)         (14,373)    
Ending balance at Dec. 31, 2008     8,968   1   34,330 (25,363) 0  
Ending balance, shares at Dec. 31, 2008         13,763,231          
Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares         2,385,715          
Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)     7,714   1   7,713      
Common stock warrants issued in connection with the 2009, 2010 and 2011 offerings     (2,863)       (2,863)      
Common stock issued upon exercise of stock options, shares         281          
Common stock issued as commitment fee in connection with SEDA, shares         58,398          
Common stock issued as commitment fee in connection with SEDA     281       281      
Stock based compensation expense for directors and employees     2,906       2,906      
Stock based compensation expense for services     1,296       1,296      
Value of common stock warrants issued (expense) in exchange for services     826       826      
Net loss     (18,387)         (18,387)    
Ending balance at Dec. 31, 2009     741   2   44,489 (43,750) 0  
Ending balance, shares at Dec. 31, 2009         16,207,625          
Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares         2,700,000          
Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)     15,235       15,235      
Purchase of 675,000 shares of treasury stock     (3,849)           (3,849)  
Common stock warrants issued in connection with the 2009, 2010 and 2011 offerings     (2,466)       (2,466)      
Fair value of shares mandatorily redeemable for cash upon exercise of warrants     (785)       (785)      
Common stock issued upon exercise of stock options, shares         53,500          
Common stock issued upon exercise of stock options     254       254      
Issuance of restricted stock units, shares         86,634          
Issuance of restricted stock units     207       207      
Stock based compensation expense for directors and employees     3,625       3,625      
Stock based compensation expense for services     743       743      
Value of common stock warrants issued (expense) in exchange for services     718       718      
Net loss (11,993)   (11,993)         (11,993)    
Ending balance at Dec. 31, 2010 2,430   2,430   2   62,020 (55,743) (3,849)  
Ending balance, shares at Dec. 31, 2010         19,047,759          
Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively) shares         18,650,000          
Issuance of common stock, for cash (net of offering costs of $796, $636, $965 and $1,890 for the period ending 2008 to 2011 respectively)     18,615   2   18,613      
Common stock warrants issued in connection with the 2009, 2010 and 2011 offerings     (12,709)       (12,709)      
Issuance of stock in lieu of cash bonus, shares         147,040          
Issuance of stock in lieu of cash bonus     171       171      
Issuance of restricted stock units, shares         220,729          
Issuance of restricted stock units     256       256      
Issuance of common stock for services, shares         53,558          
Issuance of common stock for services     73       73      
Issuance of common stock upon exercise of warrant, shares         150,000          
Issuance of common stock upon exercise of warrants     150       150      
Issuance of common stock in cashless exchange of outstanding warrants, shares         4,151,000          
Issuance of common stock in cashless exchange of outstanding warrants     3,120       3,120      
Issuance of common stock related to acquisition of Apthera Inc., shares         4,974,090          
Issuance of common stock related to acquisition of Apthera Inc.     6,367   1   6,366      
Issuance of common stock subject to employee termination agreements, shares         398,453          
Issuance of common stock subject to employee termination agreements     350       350      
Issuance of common stock subject to Employee Stock Purchase Plan, shares         18,824          
Issuance of common stock subject to Employee Stock Purchase Plan     15       15      
Stock based compensation expense for directors and employees     2,774       2,774      
Stock based compensation expense for services     (123)       (123)      
Value of common stock warrants issued (expense) in exchange for services     108       108      
Net loss (11,485)   (11,485)         (11,485)    
Ending balance at Dec. 31, 2011 $ 10,112   $ 10,112   $ 5   $ 81,184 $ (67,228) $ (3,849)  
Ending balance, shares at Dec. 31, 2011         47,811,453